A new SERS strategy for quantitative analysis of trace microalbuminuria based on immunorecognition and graphene oxide nanoribbon catalysis
Received 20 May 2018
Accepted for publication 2 August 2018
Published 5 October 2018 Volume 2018:13 Pages 6099—6107
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Linlin Sun
Guiqing Wen,1,2,* Qi Jing,1,2,* Aihui Liang,1,2 Zhiliang Jiang1,2
1Key Laboratory of Ecology of Rare and Endangered Species and Environmental Protection (Guangxi Normal University), Ministry of Education, Guangxi Key Laboratory of Environmental Pollution Control Theory and Technology, Guilin, China; 2Department of Environment Science, College of Environment and Resources, Guangxi Normal University, Guilin, China
*These authors contributed equally to this work
Background: Microalbuminuria (mAlb) detection is essential for the diagnosis and prognosis of nephrotic patients and hypoproteinemia. In this article, we develop a new surface-enhanced Raman scattering (SERS) quantitative analysis method to detect mAlb in urine.
Methods: Combined the mAlb immunoreaction with gold nanoreaction of graphene oxide nanoribbons (GONR)-HAuCl4-H2O2, and used Victoria blue B (VBB) as molecular probe with a SERS peak at 1,615 cm-1, a new SERS strategy for quantitative analysis of trace mAlb in urine was established.
Results: The linear range of SERS quantitative analysis method is from 0.065 to 2.62 ng/mL, with a detection limit of 0.02 ng/mL. The SERS method was applied to analysis of mAlb in urine with good accuracy and reliability, the relative standard deviation is 0.49%–2.28% and the recovery is 96.9%–109.8%.
Conclusion: This study demonstrated that the new SERS quantitative analysis method is of high sensitivity, good selectivity and simplicity. It has been applied to analysis of mAlb in urine, with satisfactory results.
Keywords: graphene oxide nanoribbon, nanocatalysis, microalbumin immunoreaction, gold nanoreaction, SERS
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]